Measurement of oxidized lipoprotein (a) in patients with acute coronary syndromes and stable coronary artery disease by 2 ELISAs: Using different capture antibody against oxidized lipoprotein (a) or oxidized LDL |
| |
| Authors: | Jun-jun Wang Ai-zhong Han Yang Meng Jian-bin Gong Chun-ni Zhang Ke Li Yu-Xiu Liu |
| |
| Affiliation: | 1. Department of Biochemistry, Jinling Hospital, Clinical School of Medicine, Nanjing University, Nanjing 210002, P.R. China;2. Department of Cardiopathy, Jinling Hospital, P.R. China;3. Department of Scientific Research and Education, Jinling Hospital, #305 East Zhongshan Road, Nanjing 210002, P.R. China;1. National Research Centre “Kurchatov Institute” B.P. Konstantinov Petersburg Nuclear Physics Institute, Orlova Roscha, 188300 Gatchina, Russia;2. St. Petersburg Electrotechnical University “LETI”, Physics Department, Prof. Popov 5, 197376 St. Petersburg, Russia;3. M.V. Lomonosov Moscow State University, Chemistry Department, Vorob’evy gory 1, 119991 Moscow, Russia |
| |
| Abstract: | ![]()
ObjectiveTo evaluate clinical value of oxidized lipoprotein(a) [ox-Lp(a)] levels.Design and methodsOx-Lp(a) were measured by 2 ELISAs using antibodies against ox-Lp(a) [ox-Lp(a)1] or oxidized low-density lipoprotein [ox-Lp(a)2], and studied in 161 acute coronary syndromes (ACS) patients, 114 stable coronary artery disease (CAD) and 100 control subjects.ResultsOx-Lp(a)1 was found related with ox-Lp(a)2 (r = 0.864, P = 0.000). Controlling for plasma lipids, Lp(a) and clinical characteristics, odds ratios of ox-Lp(a)1 on ACS and stable CAD were 5.06 (95% confidence interval 1.82–14.04) and 2.20 (0.78–6.22); those of ox-Lp(a)2 were 3.37 (1.07–10.63) and 1.35 (0.41–4.48), respectively. Receiver-operating characteristic curve analysis confirmed that performances of ox-Lp(a)1 were significantly superior to those for ox-Lp(a)2 in ACS (area: 0.803 vs. 0.723, P < 0.001) and stable CAD (area: 0.670 vs. 0.607, P < 0.01).ConclusionOx-Lp(a) levels using antibodies against ox-Lp(a) may represent a better risk marker than those using antibodies against oxidized low-density lipoprotein for ACS and stable CAD. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
